CY2143B1 - Sustained release tablets containing bupropion - Google Patents

Sustained release tablets containing bupropion

Info

Publication number
CY2143B1
CY2143B1 CY9900040A CY9900040A CY2143B1 CY 2143 B1 CY2143 B1 CY 2143B1 CY 9900040 A CY9900040 A CY 9900040A CY 9900040 A CY9900040 A CY 9900040A CY 2143 B1 CY2143 B1 CY 2143B1
Authority
CY
Cyprus
Prior art keywords
sustained release
tablets containing
release tablets
hydrochloride
containing bupropion
Prior art date
Application number
CY9900040A
Other languages
English (en)
Inventor
Jennie Sue Galloway Ludwig
Joel Elmore Sutton Jr
William Leroy Bass Jr
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10720358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2143(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of CY2143B1 publication Critical patent/CY2143B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • General Preparation And Processing Of Foods (AREA)
CY9900040A 1992-08-14 1999-11-29 Sustained release tablets containing bupropion CY2143B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929217295A GB9217295D0 (en) 1992-08-14 1992-08-14 Controlled released tablets

Publications (1)

Publication Number Publication Date
CY2143B1 true CY2143B1 (en) 2002-06-21

Family

ID=10720358

Family Applications (1)

Application Number Title Priority Date Filing Date
CY9900040A CY2143B1 (en) 1992-08-14 1999-11-29 Sustained release tablets containing bupropion

Country Status (21)

Country Link
US (1) US5427798A (fr)
EP (1) EP0656775B1 (fr)
JP (1) JPH08500110A (fr)
KR (1) KR100294154B1 (fr)
AT (1) ATE161422T1 (fr)
AU (1) AU677595B2 (fr)
CA (1) CA2142320C (fr)
CY (1) CY2143B1 (fr)
DE (1) DE69316015T2 (fr)
ES (1) ES2111168T3 (fr)
GB (1) GB9217295D0 (fr)
GR (1) GR3025794T3 (fr)
HK (1) HK1004323A1 (fr)
IL (1) IL106693A (fr)
LU (1) LU90656I2 (fr)
MX (1) MX9304967A (fr)
NZ (1) NZ254947A (fr)
SG (1) SG43911A1 (fr)
TW (1) TW260607B (fr)
WO (1) WO1994004138A1 (fr)
ZA (1) ZA935942B (fr)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5616344A (en) * 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
SI1017392T1 (en) * 1997-09-25 2002-12-31 Bayer Aktiengesellschaft Medicament formulation with a controlled release of an active agent
US5968553A (en) * 1997-12-30 1999-10-19 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
US6221917B1 (en) 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
JP2002501890A (ja) * 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（＋）−ビュープロピオンの薬学的使用
AU2349999A (en) * 1998-01-29 1999-08-16 Sepracor, Inc. Pharmacological uses of pure (+) -bupropion
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
CA2318738A1 (fr) * 1998-01-29 1999-08-05 Sepracor Inc. Procedes et compositions de (-)-bupropion optiquement pur destines a faciliter la desaccoutumance au tabac et au traitement de douleurs et d'autres troubles
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US6153223A (en) * 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) * 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6589553B2 (en) * 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
USD430285S (en) * 1999-04-16 2000-08-29 Merck & Co., Inc. Tablet
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
NZ518739A (en) * 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
CA2796884A1 (fr) * 2001-02-08 2002-08-15 Andrx Pharmaceuticals, Inc. Forme posologique orale a liberation regulee amelioree
ITMI20011457A1 (it) * 2001-07-09 2003-01-09 Valpharma Sa Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
MXPA04011203A (es) 2002-05-17 2005-07-14 Univ Duke Metodo para tratar la obesidad.
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
CA2501324A1 (fr) * 2002-10-30 2004-05-21 Pharmacia Corporation Comprimes oraux a liberation etendue et procedes de fabrication et d'utilisation associes
US20040096497A1 (en) * 2002-11-19 2004-05-20 Ponder Garratt W. Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
EP2316456B1 (fr) * 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) * 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
CN1819821B (zh) * 2003-08-08 2010-10-13 拜奥维尔实验室国际股份有限公司 盐酸安非他酮的改良释放片剂
CA2553207A1 (fr) 2004-01-13 2005-08-04 Kishore M. Gadde Compositions anticonvulsives, medicament antipsychotique et leurs methodes d'utilisation permettant d'influer sur la perte de poids
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005107806A1 (fr) * 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions agissant sur une perte de poids
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20060099262A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
US8586085B2 (en) 2004-11-08 2013-11-19 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion
GB0425445D0 (en) * 2004-11-18 2004-12-22 Smithkline Beecham Corp Novel compositions
KR100670798B1 (ko) 2004-12-17 2007-01-17 한국전자통신연구원 데이터베이스 캐시 시스템
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007002597A2 (fr) * 2005-06-27 2007-01-04 Biovail Laboratories International S.R.L. Formulations a liberation modifiee d'un sel de bupropion
AU2006304889A1 (en) * 2005-10-14 2007-04-26 H. Lundbeck A/S Stable pharmaceutical formulations containing escitalopram and bupropion
AU2006308635A1 (en) * 2005-10-14 2007-05-10 H. Lundbeck A/S Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
WO2007067341A2 (fr) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions et procedes d’augmentation de la sensibilite a l’insuline
WO2007062228A1 (fr) * 2005-11-28 2007-05-31 Orexigen Therapeutics, Inc. Formulation de zonisamide a liberation prolongee
US8372861B2 (en) * 2006-02-27 2013-02-12 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of the unfolded protein response and methods for their use
WO2007103366A2 (fr) 2006-03-07 2007-09-13 Osteoscreen Ip, Llc RENFORCEMENT DE L'OS ET DU CARTILAGE PAR UN INHIBITEUR DE LA HMG Co-A RÉDUCTASE
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
CN101808634A (zh) 2006-06-13 2010-08-18 利兰·斯坦福青年大学托管委员会 半胱氨酸蛋白酶的环氧化物抑制剂
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
US7674479B2 (en) * 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
WO2008023390A2 (fr) * 2006-08-21 2008-02-28 Jubilant Organosys Limited Composition pharmaceutique de chlorhydrate de bupropion à libération modifiée
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
KR101479324B1 (ko) 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP2142183A2 (fr) 2007-04-09 2010-01-13 Sepracor Inc. Procédés et compositions destinées au traitement de troubles respiratoires liés au sommeil
US20090023744A1 (en) * 2007-06-18 2009-01-22 The General Hospital Corporation Combination therapy for depression
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
US9339500B2 (en) 2008-03-04 2016-05-17 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
LT2273983T (lt) 2008-05-09 2016-10-25 Grünenthal GmbH Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija
CA2725930A1 (fr) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Procedes pour traiter des pathologies des graisses viscerales
TW201039815A (en) 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
TW201105316A (en) * 2009-07-22 2011-02-16 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
KR101747156B1 (ko) 2009-07-22 2017-06-27 그뤼넨탈 게엠베하 산화-안정화된 탬퍼-내성 용량형
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
CN102821757B (zh) 2010-02-03 2016-01-20 格吕伦塔尔有限公司 通过挤出机制备粉末状药物组合物
RU2607499C2 (ru) 2010-09-02 2017-01-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер
MX2013002377A (es) 2010-09-02 2013-04-29 Gruenenthal Gmbh Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
US9085570B2 (en) 2010-10-11 2015-07-21 The Board Of Trustees Of The Leland Stanford Junior University Substituted benzamides and their uses
EP2632927B1 (fr) 2010-10-26 2016-02-10 Mars, Incorporated Boronates en tant qu'inhibiteurs d'arginase
EA201400173A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
SG10201607685SA (en) 2011-11-21 2016-11-29 Calithera Biosciences Inc Heterocyclic inhibitors of glutaminase
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
SG11201406518XA (en) 2012-04-12 2014-11-27 Univ Leland Stanford Junior Substituted benzamides and their uses
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2013271622B2 (en) 2012-06-06 2018-03-01 Nalpropion Pharmaceuticals Llc Methods of treating overweight and obesity
PL2920168T3 (pl) 2012-11-16 2022-01-03 Calithera Biosciences, Inc. Heterocykliczne inhibitory glutaminazy
EP4218829A3 (fr) 2013-03-15 2023-08-16 The Board of Trustees of the Leland Stanford Junior University Composés de sonde basée sur l'activité, compositions et méthodes d'utilisation
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
CA2917136C (fr) 2013-07-12 2022-05-31 Grunenthal Gmbh Forme posologique inviolable contenant un polymere d'ethylene-acetate de vinyle
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
JP6798890B2 (ja) 2014-06-13 2020-12-09 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤との併用療法
WO2016022969A1 (fr) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Formes cristallines d'inhibiteurs de glutaminase
EP3180332B1 (fr) 2014-08-13 2021-10-27 Eolas Therapeutics Inc. Difluoropyrrolidines en tant que modulateurs des récepteurs de l'orexine
EP3212195A4 (fr) 2014-10-31 2018-06-06 The Regents of The University of California Compositions et méthodes de traitement d'un dysfonctionnement cognitif associé au vih
CN114044760A (zh) 2015-03-10 2022-02-15 奥瑞基尼探索技术有限公司 作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
US10143699B2 (en) 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
KR102305932B1 (ko) * 2015-06-29 2021-09-28 플로로놀 인코퍼레이티드 갈조류의 고체 약제학적 조성물
CA2998259A1 (fr) 2015-09-10 2017-03-16 Grunenthal Gmbh Protection contre un surdosage par voie orale a l'aide de formulations a liberation immediate dissuasives d'abus
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CA3000996A1 (fr) 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Polytherapie a l'aide d'inhibiteurs de glutaminase et agents immuno-oncologiques
SG10201911406TA (en) 2015-10-30 2020-01-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
MX2018005872A (es) 2015-11-16 2019-05-16 Ichorion Therapeutics Inc Profarmacos de acido nucleico.
KR20180107232A (ko) 2016-02-12 2018-10-01 아스트라제네카 아베 오렉신 수용체 조정제로서의 할로-치환된 피페리딘
WO2017210565A1 (fr) 2016-06-03 2017-12-07 Prisident And Fellows Of Harvard College Composés antifongiques
WO2018039612A1 (fr) 2016-08-26 2018-03-01 The Regents Of The University Of California Compositions et méthodes favorisant la croissance des cheveux au moyen d'inhibiteurs de mpc1
EP3510040A4 (fr) 2016-09-09 2020-06-03 Calithera Biosciences, Inc. Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation
US10980767B2 (en) 2016-09-09 2021-04-20 The Regents Of The University Of California Estrogen receptor ligands, compositions and methods related thereto
WO2018058029A1 (fr) 2016-09-26 2018-03-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de protéine chromobox et leurs utilisations
CA3038528A1 (fr) 2016-09-28 2018-04-05 Medicon Pharmaceuticals, Inc. Compositions et methodes de traitement de troubles ophtalmologiques
HRP20230634T1 (hr) 2016-09-28 2023-10-13 Medicon Pharmaceuticals, Inc. Pripravci za liječenje oftalmoloških stanja
AU2017356942A1 (en) 2016-11-08 2019-05-23 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
ES2970715T3 (es) 2016-12-22 2024-05-30 Prec Pharmaceuticals Inc Composiciones y métodos para inhibir la actividad de la arginasa
AU2017382460A1 (en) 2016-12-23 2019-05-02 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
CN110430880A (zh) 2017-01-18 2019-11-08 范德比尔特大学 作为选择性bmp抑制剂的稠合杂环化合物
MX2019010096A (es) 2017-02-24 2020-01-09 Merck Patent Gmbh Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa.
WO2018178947A2 (fr) 2017-03-31 2018-10-04 Aurigene Discovery Technologies Limited Composés et compositions pour le traitement de troubles hématologiques
WO2018209288A1 (fr) 2017-05-12 2018-11-15 Massachusetts Institute Of Technology Complexes d'arn double brin de protéine argonaute et leurs utilisations
WO2018223032A1 (fr) 2017-06-02 2018-12-06 Stealth Biotherapeutics Corp. Formes cristallines de sel de sbt-20
MX2019015475A (es) 2017-06-30 2020-02-19 Univ California Composiciones y metodos para modular el crecimiento del cabello.
WO2019018539A1 (fr) 2017-07-19 2019-01-24 California Institute Of Technology Procédés de préparation de composés contenant bis-tétrahydroisoquinoline
EA202090536A1 (ru) 2017-10-11 2020-07-22 Ориджен Дискавери Текнолоджис Лимитед Кристаллические формы 3-замещенного 1,2,4-оксадиазола
CN117064897A (zh) 2017-10-31 2023-11-17 库里斯公司 用于治疗血液病的化合物和组合物
CN111372584A (zh) 2017-11-03 2020-07-03 奥瑞基尼探索技术有限公司 Tim-3和pd-1途径的双重抑制剂
EP3706798A1 (fr) 2017-11-06 2020-09-16 Aurigene Discovery Technologies Limited Thérapies conjointes à des fins d'immunomodulation
AR113995A1 (es) 2017-12-22 2020-07-08 Medimmune Ltd Moduladores de molécula pequeña del domino de btb de keap1
US10745400B2 (en) 2018-03-14 2020-08-18 Vanderbuilt University Inhibition of BMP signaling, compounds, compositions and uses thereof
US10933084B2 (en) 2018-04-12 2021-03-02 MatRx Therapeutics Corporation Compositions and methods for treating elastic fiber breakdown
WO2019217450A1 (fr) 2018-05-08 2019-11-14 Rhode Island Hospital Anticorps anti-chi3l1 pour la détection et/ou le traitement d'une stéatose hépatique non alcoolique / stéatohépatite non alcoolique et des complications subséquentes
EP3813841A4 (fr) 2018-06-29 2022-03-09 The Regents Of The University Of California Nouvelles pinces moléculaires contre des troubles neurologiques et des infections virales
SG11202100429TA (en) 2018-07-27 2021-02-25 California Inst Of Techn Cdk inhibitors and uses thereof
AU2019336698A1 (en) 2018-09-05 2021-03-25 Aztherapies, Inc. Methods of treating cytokine release syndrome
CA3117695A1 (fr) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Formes cristallines d'un inhibiteur d'alk2
CN113574055B (zh) 2019-01-18 2024-07-23 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
WO2020154656A1 (fr) 2019-01-25 2020-07-30 Brown University Compositions et procédés pour traiter, prévenir ou inverser une inflammation et des troubles associés à l'âge
WO2020160323A2 (fr) 2019-01-31 2020-08-06 Elektrofi, Inc. Formation et morphologie de particules
CN113573709A (zh) 2019-03-14 2021-10-29 阿斯利康(瑞典)有限公司 用于体重减轻的兰比斯特
CN113874375A (zh) 2019-06-03 2021-12-31 株式会社大分大学先端医学研究所 用于治疗狂犬病的环状酰胺化合物及其方法
AU2020344675A1 (en) 2019-09-13 2022-03-31 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
CA3157798A1 (fr) 2019-11-12 2021-05-20 Zhongli Gao Heteroarylaminosulfonamides a 6 chainons pour le traitement de maladies et d'etats medies par une activite cftr deficiente
WO2021113809A1 (fr) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides et leurs procédés d'utilisation
WO2021113806A1 (fr) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides et leurs procédés d'utilisation
CN114901290A (zh) 2019-12-16 2022-08-12 蔚山科学技术院 抑制血管新生因子的化合物及其用途
WO2021158959A2 (fr) 2020-02-07 2021-08-12 Elektrofi, Inc. Particules peptidiques et procédés de formation
WO2021168271A1 (fr) 2020-02-19 2021-08-26 Elektrofi, Inc. Formation de gouttelettes et morphologie de particules
CN115484934A (zh) 2020-04-17 2022-12-16 伊勒卓菲公司 通过连续液滴形成和脱水形成颗粒的方法
WO2021263072A1 (fr) 2020-06-25 2021-12-30 Dana-Farber Cancer Institute, Inc. Méthodes de traitement d'une maladie
CN111830151B (zh) * 2020-07-01 2021-05-04 迪沙药业集团有限公司 盐酸安非他酮组合物质量控制用系统适用性对照品
CA3191164A1 (fr) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. 1,2,4-oxadiazoles substitues utilises en tant qu'inhibiteurs de petites molecules de la protease 28 specifique de l'ubiquitine
CA3191163A1 (fr) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Inhibiteurs a petites molecules pyrimidine-thieno-pyridine tricycliques fusionnees de la protease 28 specifique de l'ubiquitine
US20230271918A1 (en) 2020-08-10 2023-08-31 Dana-Farber Cancer Institute, Inc. Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
EP4232161A1 (fr) 2020-10-23 2023-08-30 Dana-Farber Cancer Institute, Inc. Inhibiteurs covalents de créatine kinase (ck) et leurs utilisations dans le traitement et la prévention du cancer
WO2022133237A2 (fr) 2020-12-18 2022-06-23 Cornell University Méthodes de traitement de troubles neurodégénératifs et de cancers liés à stat3 au moyen de suppresseurs de fuite d'électrons
IL303813A (en) 2020-12-21 2023-08-01 Univ Cornell A peptide-linked drug delivery system
WO2022150574A1 (fr) 2021-01-08 2022-07-14 Cornell University Inhibiteurs de la lipoamide déshydrogénase de mycobacterium tuberculosis
EP4323356A1 (fr) 2021-04-13 2024-02-21 Nuvalent, Inc. Hétérocycles amino-substitués pour le traitement de cancers avec des mutations egfr
EP4396176A1 (fr) 2021-09-03 2024-07-10 Genzyme Corporation Composés indoles et leurs utilisations dans le traitement de la fibrose kystique
KR20240076791A (ko) 2021-09-03 2024-05-30 젠자임 코포레이션 인돌 화합물 및 사용 방법
IL311444A (en) 2021-10-01 2024-05-01 Nuvalent Inc Solid forms, pharmaceutical preparations and preparation of macrocyclic heteroaromatic ether compounds
KR20240095536A (ko) 2021-10-01 2024-06-25 뉴베일런트, 아이엔씨. 헤테로방향족 매크로사이클릭 에테르 화합물을 사용한 고형 종양의 치료 방법
WO2023187422A1 (fr) 2022-03-31 2023-10-05 Revolo Biotherapeutics Limited Compositions et leur utilisation dans des procédés pour traiter une inflammation intestinale
WO2023196910A1 (fr) 2022-04-07 2023-10-12 Nuvalent, Inc Méthodes de traitement d'une tumeur solide à l'aide de (19r)-5-chloro-3-éthyl-16-fluoro-10,19-diméthyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6. 08,12.013,18]pentacosa-1(24), 2(6),4,8,11,13,15,17,21(25),22-décaén-22-amine
TW202400608A (zh) 2022-04-07 2024-01-01 美商努法倫特公司 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
WO2023212721A1 (fr) 2022-04-29 2023-11-02 Elektrofi, Inc. Suspensions injectables
WO2023223015A1 (fr) 2022-05-16 2023-11-23 Revolo Biotherapeutics Limited Méthodes et compositions de prévention ou de traitement d'allergies alimentaires
WO2023250157A1 (fr) 2022-06-24 2023-12-28 Cornell University Inhibiteurs de mycobacterium tuberculosis lipoamide déshydrogénase
WO2024013209A1 (fr) 2022-07-13 2024-01-18 Astrazeneca Ab Inhibiteurs de pcsk9 et leurs procédés d'utilisation
WO2024036098A1 (fr) 2022-08-12 2024-02-15 Nuvalent, Inc. Composés d'éther macrocycliques hétéroaromatiques
WO2024036097A1 (fr) 2022-08-12 2024-02-15 Nuvalent, Inc. Composés d'éther macrocycliques hétéroaromatiques et isotopologues de ceux-ci
WO2024073334A1 (fr) 2022-09-26 2024-04-04 Rose Research Center, Llc Combinaison destinée à être utilisée dans un procédé de prévention de gain de poids
WO2024086634A1 (fr) 2022-10-19 2024-04-25 Nuvalent, Inc. Agents chimiothérapeutiques à base d'éther macrocyclique hétéroaromatique

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759838A (fr) * 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US3885046A (en) * 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
CA948388A (en) * 1970-02-27 1974-06-04 Paul B. Hansen Pattern bonded continuous filament web
US4347257A (en) * 1979-10-09 1982-08-31 Burroughs Wellcome Co. Prolactin suppression in mammals
JPS56104819A (en) * 1980-01-21 1981-08-20 Wellcome Found Blending agent
US4347176A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making same
US4347178A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making
US4347177A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making them
US4356165A (en) * 1980-04-14 1982-10-26 Burroughs Wellcome Co. Bupropion radioimmunoassay, and kit
US4347382A (en) * 1980-04-15 1982-08-31 Burroughs Wellcome Co. 3H Labeled compounds
US4355179A (en) * 1980-04-14 1982-10-19 Burroughs Wellcome Co. Radioactive nuclide labeled propiophenone compounds
US4425363A (en) * 1981-05-14 1984-01-10 Burroughs Wellcome Co. Treatment of tardive dyskinesia in mammals
US4435449A (en) * 1981-05-14 1984-03-06 Burroughs Wellcome Co. Treatment of minimal brain dysfunction (MBD)
US4393078A (en) * 1982-03-15 1983-07-12 Burroughs Wellcome Co. Bupropion and ethanol
US4438138A (en) * 1982-12-06 1984-03-20 Burroughs Wellcome Co. Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
US4507323A (en) * 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
DE10075031I2 (de) * 1984-08-17 2004-07-01 Wellcome Found Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
AU657973B2 (en) * 1991-05-07 1995-03-30 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation

Also Published As

Publication number Publication date
AU4725893A (en) 1994-03-15
JPH08500110A (ja) 1996-01-09
KR950702827A (ko) 1995-08-23
DE69316015T2 (de) 1998-04-16
DE69316015D1 (de) 1998-02-05
MX9304967A (es) 1994-05-31
LU90656I2 (fr) 2001-01-15
TW260607B (fr) 1995-10-21
ATE161422T1 (de) 1998-01-15
ZA935942B (en) 1995-02-13
US5427798A (en) 1995-06-27
KR100294154B1 (ko) 2001-09-17
AU677595B2 (en) 1997-05-01
GR3025794T3 (en) 1998-03-31
IL106693A (en) 1997-06-10
IL106693A0 (en) 1993-12-08
SG43911A1 (en) 1997-11-14
EP0656775B1 (fr) 1997-12-29
NZ254947A (en) 1996-04-26
WO1994004138A1 (fr) 1994-03-03
EP0656775A1 (fr) 1995-06-14
ES2111168T3 (es) 1998-03-01
GB9217295D0 (en) 1992-09-30
HK1004323A1 (en) 1998-11-20
CA2142320C (fr) 2001-10-09
CA2142320A1 (fr) 1994-03-03

Similar Documents

Publication Publication Date Title
IL106693A0 (en) Controlled sustained release tablets
USD432231S (en) Plunger rod
USD400672S (en) Pharmaceutical tablet
USD344889S (en) Child-proof tablet dispenser
USD336183S (en) Mobile retail-display stand
USD341134S (en) Keyboard
USD272231S (en) Clip for holding a gas pump nozzle trigger in the open position
USD336014S (en) Taco holder
USD361675S (en) Chair
USD361383S (en) Portable limb support
USD344437S (en) Wrench for a gas meter
USD334199S (en) Fuel dispenser
USD376644S (en) Pharmaceutical tablet
USD311918S (en) Telephone set
USD358017S (en) Object for use in meditation and tranquilition
USD341038S (en) Chair
USD372047S (en) Pen
USD356306S (en) Touchscreen stylus
USD286402S (en) Combination handset telephone and stand set
USD422815S (en) Smoothly contoured chair with cushions
USD423260S (en) Mesh back chair with cushions
USD365463S (en) Computer desk
USD382595S (en) Combined writing tablet and storage tray
USD275045S (en) Combined bed and control unit for an industrial oxygen concentrator or the like
USD356174S (en) Pocket torch